AMAG Pharmaceuticals, Inc. to Host Conference Call on October 23, 2013 at 8:00
a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2013
WALTHAM, Mass., Oct. 17, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced it will report unaudited consolidated financial
results for the quarter and nine months ended September 30, 2013 before the
U.S. financial markets open on Wednesday, October 23, 2013. The announcement
will be followed by a conference call and webcast with slides at 8:00 a.m. ET
during which management will provide a business update and review third
quarter financial results.
To access the conference call via telephone, please dial (877) 412-6083 from
the United States or (702) 495-1202 for international access. A telephone
replay will be available from approximately 11:00 a.m. ET on October 23, 2013
through midnight on October 30, 2013. To access a replay of the conference
call, dial (855) 859-2056 from the United States or (404) 537-3406 for
international access. The pass code for the live call and the replay is
The call will be webcast with slides and accessible through the Investors
section of the company's website at www.amagpharma.com. The webcast replay
will be available from approximately 11:00 a.m. ET on October 23, 2013 through
midnight November 21, 2013.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please
AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.; MuGard is a registered trademark of Access
CONTACT: AMAG Pharmaceuticals, Inc. contact:
Amy Sullivan, 617-498-3303
Press spacebar to pause and continue. Press esc to stop.